Many children with Tourette Syndrome require pharmacologic therapy to alleviate their symptoms of accompanying attention deficit hyperactivity disorder (ADHD). Although psychostimulant medications (methylphenidate, dextroamphetamine, or pemoline) are usually considered the drugs of choice for ADHD, in patients with TS these medications may provoke or exacerbate tic symptoms. Hence, the goal of this research project is to establish alternative therapies for ADHD in TS patients. Children between the ages 7 to 13 years with TS and ADHD, who are of normal intellect and do not have psychiatric disease, will be treated in a randomized double-blind, placebo controlled protocol with each of the following: clonidine, desipramine, and placebo. At the completion of each treatment period, measures will evaluate ADHD, obsessive compulsive symptoms (OCS) and the severity of motor/phonic tics. Statistical analyses will establish: 1) the beneficial effect of clonidine and desipramine as compared to placebo in children with ADHD and TS and 2) the effect of tic severity and the presence of OCS on the ability of these drugs to improve behaviors. Harvey S. Singer, MD Johns Hopkins Hospital Baltimore, MD Award: $25,000 Tourette Association of America Inc. – Research Grant Award 1988